Invivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial | Invivyd
PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in Exploratory Analysis Ongoing Phase 3 Clinical Trial May be useful for PRE-EXPOSURE PROPHYLAXIS (Prep) in immunocompromised & immunocompetent